Navigation Links
Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
Date:5/27/2008

become the global leader in cocoa research. For more information, visit http://www.cocoapro.com. For more information about the Mars, Incorporated cocoa sustainability program, visit http://www.cocoasustainability.mars.com.

About Mars Botanical

Mars Botanical, headquartered in Rockville, Maryland, is a newly-established division of Mars, Incorporated. The mission of Mars Botanical is to further develop leading edge science and technologies in the field of phytonutrients with the goal of creating new plant-derived products aimed at improving human health, and do so in a sustainable way that helps both farming communities and their local environment. Mars, Incorporated scientists and colleagues at leading research institutions are dedicated to unlocking the full nutritional and medical potential of cocoa flavanols. For more information, visit http://www.marsbotanical.com.


'/>"/>
SOURCE Mars, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
9. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc., an inhalation drug delivery company, today announced that ... A financing round, exceeding the targeted total raise amount ... the Series A round will be utilized to continue ... now have the runway and resources to effectively demonstrate ... Rob Neville, CEO of Savara. ,, The company ...
(Date:12/16/2009)... ChemoCentryx, Inc. today announced that it ... clinical trial of CCX354, an orally-bioavailable, novel, small ... chemokine receptor for the treatment of rheumatoid arthritis ... and selective antagonist of CCR1, a chemokine receptor ... as monocytes and macrophages, associated with the inflammation ...
(Date:12/16/2009)... December 16 , ... With Microplasmin Recruits a Total of Over,640 ... ThromboGenics NV (Euronext Brussels: THR), ... development of innovative treatments for eye,disease, vascular ... has completed,the enrolment of the second Phase ...
Breaking Medicine Technology:Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4NIEHS awards Recovery Act funds to focus more research on health and safety of nanomaterials 10801 1NIEHS awards Recovery Act funds to focus more research on health and safety of nanomaterials 10801 2NIEHS awards Recovery Act funds to focus more research on health and safety of nanomaterials 10801 3NIEHS awards Recovery Act funds to focus more research on health and safety of nanomaterials 10801 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 1Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 14918 9Delcath Systems Reports Substantial Progress 6396 1Delcath Systems Reports Substantial Progress 6396 2Delcath Systems Reports Substantial Progress 6396 3Delcath Systems Reports Substantial Progress 6396 4
... Stehlin Foundation for Cancer Research Develops Innovative ... ... Almost everyone knows the devastation,that cancer brings to families, ... cancer treatment institutions.,Few, however, may be familiar with the CHRISTUS ...
... New drug is company,s third to enter human trials ... Addrenex Pharmaceuticals today,announced that the U.S. Food and Drug ... ADX415, a novel hypertension,drug. With the approval, Addrenex has ... a targeted therapy for hypertension., The phase 2 ...
Other Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415 2
(Date:12/16/2009)... Market Expansion , ... Ramat-Gan, Israel (PRWEB) December 16, ... Web sites and companies, today announced a record year of growth ... its launch on July 2008, Kampyle has processed more than 12 ... than 30,000 customers in 191 countries., , ,Kampyle pioneered the ...
(Date:12/16/2009)... SCHAFFHAUSEN, Switzerland, Dec. 16 Tyco International ... the nomination of Michael E. Daniels for election ... company,s Annual General Meeting on March 10, 2010. ... of the Global Technology Services group of International ... worldwide responsibility for IBM,s Global Services business operations ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: ... Directors and the Board of Medizone New Zealand ... Inc. holds a 50% interest, agreed on December ... reconvey to Medizone International all global marketing rights ... Chairman, Edwin G. Marshall said, "Time has eroded ...
(Date:12/16/2009)... the ,70s, study finds , , TUESDAY, Dec. 15 (HealthDay ... United States than it was more than 30 years ... compared National Health and Nutrition Examination Survey data from ... and from 8,339 black and white participants from 1999 ... old. , The prevalence of myopia increased from 25 ...
(Date:12/16/2009)... in triathalons and appeared on The Amazing Race ... to think of herself as part human, part machine. , ... 34-year-old triathlete likes to describe herself. When she,s not training ... school auditoriums or posing nude with her metal leg crossed ... latest ESPN Body Issue. , She is the ...
Breaking Medicine News(10 mins):Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4
... Interviews Available with Top Children,s Miracle Network Health Experts, SALT LAKE CITY, Oct. ... doctors and experts from 170 ... questions about Methicillin-resistant Staphylococcus Aureus ... is resistant to antibiotics, ...
... the Committee to Reduce Infection as an advisory to prevent ... hands frequently. 2. Parents, tuck a small container of ... mature enough to use it properly. 3. Educators, install ... get a hall pass and leave the,classroom to clean their ...
... in this weeks issue of the Proceedings of the National ... damaging effects of ultraviolet (UV) radiation the most abundant ... an extract of broccoli sprouts. , The results in ... that the degree of skin redness (erythema) caused by UV ...
... 22 Dialysis Corporation,of America (Nasdaq: DCAI ... third,quarter 2007 earnings after the close of the ... of America owns and operates freestanding kidney,hemodialysis centers ... Carolina and Virginia, and provides in-hospital,dialysis services on ...
... Frost & Sullivan Recognizes Achievements in Creating New Possibilities for ... ... Waters Corporation,(NYSE: WAT ) today announced that it has been ... by Frost & Sullivan.,The Market Leadership award is in recognition of ...
... quarter of the world,s adults are obese, study finds , , ... men and 30 percent of women are now overweight, and ... obese, say researchers who looked at data from 63 countries. ... and women ages 18-80 (average age 48), living on five ...
Other Medicine News:Health News:Children's Miracle Network Hospital Doctors On Call to Answer Questions About MRSA Infection 2Health News:Committee to Reduce Infection Deaths Releases 10 Lifesaving Steps to Protect Students from MRSA Infections 2Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date 2Health News:Waters Corporation Receives Market Leadership and Product Innovation Awards 2Health News:Waters Corporation Receives Market Leadership and Product Innovation Awards 3Health News:Overweight Now a Global Problem 2
... innovative & portable FireFly LED light offers ... With the new FireFly LED you'll get ... go whereever your practice demands. High center-beam ... on your procedures, while the rechargeable battery ...
Easy pull-on design for continuous chin compression and support feature our exclusive Non-Slip Dome™...
For face-lifts and submental liposuction...
Very compressive support for submental liposuction...
Medicine Products: